Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22996915 | 0.83 | KCNH2 (0.37) | CSF1RKCNH2 | |
| SCHEMBL18544261 | 0.82 | KCNH2 (0.37) | CSF1RKCNH2 | |
| SCHEMBL2821504 | 0.82 | KCNH2 (0.37) | CSF1RKCNH2 | |
| SCHEMBL1712036 | 0.80 | CLK1 (0.45) | CLK1DYRK1ACYP11B1CYP11B2 | |
| SCHEMBL1712323 | 0.78 | CCNB2 (0.36) | CSF1RKCNH2 | |
| SCHEMBL2932060 | 0.77 | PTGS2 (0.39) | KCNH2MEN1KMT2A | |
| SCHEMBL590918 | 0.76 | MAPT (0.43) | CSF1RKITCLK1DYRK1AMEN1 | |
| SCHEMBL4214405 | 0.75 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL4214402 | 0.75 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL2822572 | 0.75 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-2001887-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | CSF1R 2313/4885KIT 4633/4885CLK1 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.